⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4823795 | 0.88 | PNMT (0.37) | — | |
| SCHEMBL1171123 | 0.84 | HTR2C (0.41) | — | |
| Hydrochloric Acid SCHEMBL1171163 | 0.83 | HTR2C (0.39) | — | |
| SCHEMBL1875764 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL30144072 | 0.81 | PNMT (0.39) | — | |
| Hydrochloric Acid SCHEMBL31284488 | 0.81 | PNMT (0.39) | — | |
| SCHEMBL1371426 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL15232076 | 0.77 | — | — | |
| SCHEMBL21733173 | 0.75 | PNMT (0.33) | — | |
| SCHEMBL11791980 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144812-A1 | QUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Epizyme, Inc. (US) | 2022-05-12 | — | — | US | claimed |
| EP-3946623-A1 | QUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Epizyme Inc (US) | 2022-02-09 | — | — | EP | claimed |
| CN-113891749-A | Quinoline derivatives and their use for the treatment of cancer | 埃皮齐梅股份有限公司 | 2022-01-04 | — | — | CN | claimed |
| WO-2021063404-A1 | COMPOUND AS SMALL MOLECULE INHIBITOR PD-1/PD-L1 AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2021-04-08 | — | — | WO | claimed |
| WO-2020198567-A1 | QUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Epizyme, Inc. (US) | 2020-10-01 | — | — | WO | claimed |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| US-12247027-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-11 | — | — | US | disclosed |
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
| US-20240116930-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-11 | — | — | US | disclosed |
| US-11891387-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-06 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20150080401-A1 | Triazine Derivatives | PFIZER (US) | 2015-03-19 | — | — | US | disclosed |
| US-8933224-B2 | Triazine derivatives | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140329820-A1 | Triazine Derivatives | PFIZER INC. (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2014177977-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014177977-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS | PFIZER INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2012114252-A1 | NOVEL INDOLE AND PYRROLOPYRIDINE AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-08-30 | — | — | WO | disclosed |
| EP-1885725-B1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | EP | disclosed |
| US-20060235013-A1 | Tricyclic azole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | US | disclosed |